domo.health Launches Generative AI to Transform Homecare by Reducing Administrative Burdens and Enhancing Collaboration
plus
Actualités de Lausanne
More space for fashion: Manor launches new fashion concept and inspires customers with a modern look & feel, an attractive range and new brands
plusSchweizerischer Nationalfonds / Fonds national suisse
International law with cantonal twists
plusSchweizerischer Nationalfonds / Fonds national suisse
The tumour hacker
plusMore than a tonne of gold leaves the African continent every day undeclared
Un documentplusSchweizerischer Nationalfonds / Fonds national suisse
A breath of fresh air for vertical wind turbines
plusHARSCH increases its operational capacity with the opening of a new secure storage facility in Meyrin
plusMEDIA RELEASE: Artificial Intelligence – SUISA is committed to securing fair remuneration for its members
Artificial Intelligence – SUISA is committed to securing fair remuneration for its members The providers of AI platforms must pay fair remuneration to authors and publishers for the use of their protected works for machine-learning training ...
Un documentplusSchweizerischer Nationalfonds / Fonds national suisse
Wie Fadenwürmer altern - und was das für die Menschen bedeuten könnte
Bern (ots) - Ein Protein reduziert die Lebenserwartung von Fadenwürmern. Diese Entdeckung wirft die Frage auf, ob es beim Menschen ebenfalls den Alterungsprozess mitbewirkt. Selbst von den am besten erforschten Genen und Proteinen kennt man noch längst nicht alle Geheimnisse. Wie das Schweizer Taschenmesser haben sie zahlreiche, teilweise unbekannte Funktionen. Mit ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Covid-19: Research findings form the basis for scientific communication with public authorities
Bern (ots) - Insights into Covid-19, recommendations for health authorities and vaccines: the findings and synthesis report for the Swiss National Science Foundation's National Research Programme "Covid-19" (NRP 78) were presented today. The Swiss National Science Foundation (SNSF) launched the National Research ...
plusKOPIE VON: SwissFinTechLadies lunch in Lausanne
plusWhat changes when we fulfil the dream of living longer?
plusApproach Switzerland is born, a pure-play cyber security and privacy firm
Lausanne (ots) - Approach, a Belgian pure-play cyber security and privacy company, established for more than 20 years, with clients and partners all around the world, is proud to announce the opening of a new branch in Switzerland. Approach's goal is to build a local team of about twenty Swiss colleagues within 2 years, establish strategic partnerships, and build ...
plusDEBIOPHARM SHARES ONCOLOGY PROGRAM UPDATES AT ASCO 2023 FOR NOVEL WEE1 INHIBITOR, AND FIRST-IN-CLASS CA IX THERANOSTIC APPROACH
Lausanne, Switzerland (ots) - - Debiopharm will highlight diversified approaches and commitment to improving outcomes for patients with cancer at the 2023 American Society of Clinical Oncology Conference - A poster presentation and discussion will cover promising interim results with Debio 0123, a potent, highly ...
plusDEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
plusDEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
plusCredaris to acquire Crédits Conseils and expand its position as the leading Swiss credit broker
plusDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
plusDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
plusSwiss ICT Investor Club (SICTIC)
Successful Swiss technology startups: SICTIC again facilitates more than 100 financing rounds
plusIktos raises € 15.5m Series A round to expand its artificial intelligence-based drug discovery technologies and solutions
Paris, France and Lausanne Switzerland (ots) - ● The round is co-led by M Ventures and Debiopharm Innovation Fund with Omnes Capital; all joining as new investors ● Series A will enable Iktos to expand its AI technology platform and launch Iktos Robotics; an AI-driven automated end-to-end drug discovery service ...
plusDEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
plusDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots/PRNewswire) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a ...
plusDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...
plusSchweizerischer Nationalfonds / Fonds national suisse
She recognises "super recognisers"
plusFEI Fédération Equestre Internationale
Belgium's Ingmar De Vos re-elected for third and final term as FEI President
Cape Town, South Africa and Lausanne, Switzerland (ots/PRNewswire) - Belgium's Ingmar De Vos has been re-elected with an overwhelming majority by the Fédération Equestre Internationale (FEI) member National Federations to serve a third and final term as FEI President. The Presidential election was held during today's FEI Hybrid General Assembly held in Cape Town ...
plusDebiopharm leads $6M round for YonaLink to Scale Global Growth and Fuel Expansion of Platform Designed to Stream Clinical Trial Data
Boston, USA and Lausanne, Switzerland (ots) - - SaaS Platform Provides Missing Link in Clinical Trial Data Collection, Securely Automating Real-Time Transfer of Up-to-Date Patient Data Directly from EHRs to EDC Systems - Technology Brings New Levels of Speed, Quality and Efficiency to Clinical Trial Data Collection ...
plusScreeneo Innovation SA; Philipps
Philips Projection announces the Philips Screeneo U5.
Lausanne, Switzerland (ots/PRNewswire) - The Next Evolution in Ultra Short Throw 4K Laser Projection. Philips Projection is pleased to launch the Philips Screeneo U5, its Ultra Short Throw True 4K UHD Laser Projector that offers a 150" (381cm) breathtaking visual experiences from only 16.5 inches (42cm) away. In continuation to the success of the Screeneo U4 UST projector, the company brings the next evolution to the ...
plusDEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY
Lausanne, Switzerland (ots) - Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay ...
plusBIG IMPACT, SMALL PACKAGE: DEBIOPHARM LAUNCHES A WAZOKU OPEN-INNOVATION CHALLENGE FOR SMALL ANTIBODY DRUG CONJUGATE TECHNOLOGY
Lausanne, Switzerland (ots) - · Currently approved Antibody-Drug Conjugates (ADCs) are large molecules (150 kDa) composed of an antibody, a cytotoxic payload, and a linker connecting the two precedent elements · Debiopharm has launched an ADC Innovation Challenge to a pool of international “problem Solvers” ...
plus
1234567Suivant